Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/21555
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorGonzález Pérez, Javier Mauricio-
dc.contributor.authorRodríguez Jaramillo, Carlos Andrés-
dc.contributor.authorAgudelo Pérez, María-
dc.contributor.authorZuluaga Salazar, Andrés Felipe-
dc.contributor.authorVesga Meneses, Omar-
dc.date.accessioned2021-08-06T11:33:44Z-
dc.date.available2021-08-06T11:33:44Z-
dc.date.issued2017-
dc.identifier.issn1413-8670-
dc.identifier.urihttp://hdl.handle.net/10495/21555-
dc.description.abstractABSTRACT: The current increment of invasive fungal infections and the availability of new broad- spectrum antifungal agents has increased the use of these agents by non-expert practitioners, without an impact on mortality. To improve efficacy while minimizing prescription errors and to reduce the high monetary cost to the health systems, the principles of pharmacokinetics (PK) and pharmacodynamics (PD) are necessary. A systematic review of the PD of antifungals agents was performed aiming at the practicing physician without expertise in this field. The initial section of this review focuses on the general concepts of antimicrobial PD. In vitro studies, fungal susceptibility and antifungal serum concentrations are related with different doses and dosing schedules, determining the PD indices and the magnitude required to obtain a specific outcome. Herein the PD of the most used antifungal drug classes in Latin America (polyenes, azoles, and echinocandins) is discussed.spa
dc.format.extent9spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherBrazilian Society of Infectious Diseasesspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleAntifungal pharmacodynamics : Latin America’s perspectivespa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGRIPE: Grupo Investigador de Problemas en Enfermedades Infecciosasspa
dc.identifier.doi10.1016/j.bjid.2016.09.009-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1678-4391-
oaire.citationtitleThe Brazilian Journal of Infectious Diseasesspa
oaire.citationstartpage79spa
oaire.citationendpage87spa
oaire.citationvolume21spa
oaire.citationissue1spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.publisher.placeSalvador, Brasilspa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTREVspa
dc.type.localArtículo de revisiónspa
dc.subject.decsAntifúngicos-
dc.subject.decsAntifungal Agents-
dc.subject.decsFarmacología-
dc.subject.decsPharmacology-
dc.subject.decsFarmacocinética-
dc.subject.decsPharmacokinetics-
dc.subject.decsCandidiasis-
dc.subject.decsAspergilosis-
dc.subject.decsAspergillosis-
dc.description.researchgroupidCOL0005744spa
dc.relation.ispartofjournalabbrevBraz. J. Infect. Dis.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
JavierGonzales_2017_AntifungalPharmacodynamicsLatinAmerica.pdfArtículo de revisión1.18 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons